Vicki L. Sato, Director at Denali Therapeutics Inc. (DNLI), sold 6,060 shares at $22.12 ($134K) on 2024-07-01, disclosed to the SEC on 2024-07-03.
Scheduled sale ($134k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $22.12 | 2,980 | $66K | 49.1% |
| 2 | $22.12 | 2,980 | $66K | 49.1% |
| 3 | $22.86 | 100 | $2K | 1.7% |
| Total | $22.13 avg | 6,060 | $134K | 100% |
| Filing → |
| VIR | SELL | 2026-03-03 | $416K | — | Filing → |
| VIR | SELL | 2026-02-26 | $825K | — | Filing → |
| VIR | SELL | 2026-02-03 | $170K | — | Filing → |